• C Barone, R Grillo, D Dongiovanni, N Birocco, M Rampino, M G Ruo Redda, E Garibaldi, F Munoz, G Pecorari, A Cavalot, P Garzinodemo, L Buffoni, L Ciuffreda, U Ricardi, G Cortesina, C Giordano, M Fasolis, S Berrone, O Bertetto, and M Schena.
• UOA Oncologia Medica, COES, Azienda Ospedaliera San Giovanni Battista, Torino, Italy. carla.barone@hotmail.it
• Anticancer Res. 2008 Mar 1; 28 (2B): 1285-91.

BackgroundA phase II study was carried out to investigate an induction regimen with cisplatin, paclitaxel followed by radiotherapy concurrent with weekly cisplatin for locally advanced squamous cell carcinoma of the head and neck.Patients And MethodsStage III-IV disease patients were eligible. Two cisplatin (100 mg/m2) and paclitaxel (175 mg/m2) courses were administered every 21 days followed by standard fractionated external beam radiotherapy (approximately 70 Gy), concomitant to weekly cisplatin (30 mg/m2).ResultsThirty-five patients were enrolled: over 70% had unresectable disease with bulky lesions. Grade 3-4 neutropenia developed in 14% and G3 mucositis in 23%. Locoregional control was achieved in 51%. Median time to progression and overall survival were 10,7 and 17 months respectively; 2- and 3-year survival rates were 30% and 25% respectively.ConclusionOur induction two-drug regimen followed by chemoradiotherapy with concurrent weekly cisplatin was well tolerated with low acute toxicity and good locoregional control and survival rate.

26 keywords...

hide…